New cancer drug trial halted early: what we know
Disease control
Terminated
This early-stage study tested a new drug called NM6603 in 17 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. The trial was ended early, so results are limited.
Phase: PHASE1 • Sponsor: NucMito Pharmaceuticals Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC